Led, 

Good start. I think you can add depth to this by discussing a bit about RVX-208 being an orally available  bromodomain 2 selective BET inhibitor. Talk up that it is the only selective BET inhibitor in clinical trials, that all others hit both bromodomains and thus far are limited to oncology indications and no further than Phase 2. Also touch on apoAI/HDL, atherosclerosis, plaque reduction, inflammation, complement, etc. Don't just embed the video as a way to educate about mechanism of RVX-208, but add text in your article too. 

BearDownAZ